BIDMC gets $11.5 million NCI grant
Posted 9/16/2009
Posted in
The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney.
Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.
As the only NCI-funded SPORE focused on cancers of the kidney, this grant aims to improve detection, diagnosis, treatment and prevention of kidney cancer, which affects about 54,000 Americans each year and causes approximately 14,000 deaths.
SPORE grants (Specialized Program of Research Excellence) are designed to promote interdisciplinary and translational research that rapidly moves scientific discoveries to a clinical setting to directly benefit patients. This grant is a renewal of a previous $13.3 million kidney cancer SPORE awarded to Atkins and his team of collaborators in 2003.
For more detail, click here.
Tags: